Merck KGaA, Darmstadt, Germany.
GT Communications, Shrewsbury, UK.
Curr Med Res Opin. 2022 Nov;38(11):1841-1851. doi: 10.1080/03007995.2022.2101805. Epub 2022 Jul 27.
The term, "prediabetes", describes a state of hyperglycaemia that is intermediate between true normoglycaemia and the diagnostic cut-offs for indices of glycaemia that are used to diagnose type 2 diabetes. The presence of prediabetes markedly increases the risk of developing type 2 diabetes. Numerous randomized, controlled evaluations of various agents have demonstrated significant prevention or delay of the onset of type 2 diabetes in subjects with prediabetes. Intensive lifestyle interventions and metformin have been studied most widely, with the lifestyle intervention being more effective in the majority of subjects. The application of therapeutic interventions at the time of prediabetes to preserve long-term outcomes has been controversial, however, due to a lack of evidence relating to the pathogenic effects of prediabetes and the effectiveness of interventions to produce a long-term clinical benefit. Recent studies have confirmed that prediabetes, however defined, is associated with a significantly increased risk of macrovascular and microvascular complications essentially identical to those of diabetes, and also with subclinical derangements of the function of microvasculature and neurons that likely signify increased risk of compilations in future. Normoglycaemia, prediabetes and type 2 diabetes appear to be part of a continuum of increased risk of adverse outcomes. Long-term (25-30 years) post-trial follow up of two major diabetes prevention trials have shown that short-term interventions to prevent diabetes lead to long-term reductions in the risk of complications. These findings support the concept of therapeutic intervention to preserve long-term health in people with prediabetes before type 2 diabetes becomes established.
“前驱糖尿病”一词描述的是一种高血糖状态,其血糖水平介于真正的正常血糖和用于诊断 2 型糖尿病的血糖指标的诊断切点之间。前驱糖尿病的存在显著增加了发生 2 型糖尿病的风险。大量针对各种药物的随机、对照评估已经证明,在前驱糖尿病患者中,这些药物可以显著预防或延迟 2 型糖尿病的发生。强化生活方式干预和二甲双胍的研究最为广泛,大多数患者中生活方式干预更为有效。然而,由于缺乏与前驱糖尿病的发病机制相关的证据,以及干预措施产生长期临床获益的有效性证据,因此在出现前驱糖尿病时应用治疗干预来维持长期结局一直存在争议。然而,最近的研究证实,无论如何定义前驱糖尿病,都会显著增加大血管和微血管并发症的风险,与糖尿病的风险基本相同,并且还会出现微血管和神经元功能的亚临床紊乱,这可能预示着未来并发症的风险增加。正常血糖、前驱糖尿病和 2 型糖尿病似乎是不良结局风险增加的连续体的一部分。两项主要糖尿病预防试验的长期(25-30 年)随访研究表明,预防糖尿病的短期干预可长期降低并发症的风险。这些发现支持在 2 型糖尿病确诊之前,对前驱糖尿病患者进行治疗干预以保护长期健康的理念。